NIHR Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and University of Nottingham, UK.
Nottingham Digestive Diseases Centre, Translational Medical Sciences, School of Medicine, University of Nottingham, UK.
Liver Transpl. 2024 Feb 1;30(2):170-181. doi: 10.1097/LVT.0000000000000244. Epub 2023 Aug 18.
The long-term (>5 y) outcomes following liver transplantation (LT) have not been extensively reported. The aim was to evaluate outcomes of LT recipients who have survived the first 5 years. A multicenter retrospective analysis of prospectively collected data from 3 high volume LT centers (Dallas-USA, Birmingham-UK, and Barcelona-Spain) was undertaken. All adult patients, who underwent LT since the inception of the program to December 31, 2010, and survived at least 5 years since their LT were included. Patient survival was the primary outcome. A total of 3682 patients who survived at least 5 years following LT (long-term survivors) were included. Overall, median age at LT was 52 years (IQR 44-58); 53.1% were males; and 84.6% were Caucasians. A total of 49.4% (n=1820) died during a follow-up period of 36,828 person-years (mean follow-up 10 y). A total of 80.2% (n=1460) of all deaths were premature deaths. Age-standardized all-cause mortality as compared to general population was 3 times higher for males and 5 times higher for females. On adjusted analysis, besides older recipients and older donors, predictors of long-term mortality were malignancy, cardiovascular disease, and dialysis. Implementation of strategies such as noninvasive cancer screening, minimizing immunosuppression, and intensive primary/secondary cardiovascular prevention could further improve survival.
肝移植(LT)后 5 年以上的长期结果尚未广泛报道。本研究旨在评估存活超过 5 年的 LT 受者的结局。采用多中心回顾性分析方法,对 3 个大容量 LT 中心(美国达拉斯、英国伯明翰和西班牙巴塞罗那)前瞻性收集的数据进行分析。纳入自项目启动至 2010 年 12 月 31 日期间接受 LT 且 LT 后至少存活 5 年的所有成年患者。患者生存是主要结局。共纳入 3682 例 LT 后至少存活 5 年(长期存活者)的患者。总体而言,LT 时的中位年龄为 52 岁(四分位距 44-58);53.1%为男性;84.6%为白种人。在 36828 人年的随访期间(平均随访 10 年),共有 1820 例(49.4%)患者死亡。所有死亡中,共有 1460 例(80.2%)为过早死亡。与普通人群相比,男性全因死亡率的年龄标准化比值为 3 倍,女性为 5 倍。在调整分析中,除了年龄较大的受者和供者外,恶性肿瘤、心血管疾病和透析也是长期死亡的预测因素。实施非侵入性癌症筛查、最小化免疫抑制和强化原发性/继发性心血管预防等策略可能会进一步提高生存率。